Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04097405 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

A Phase 1 study, sponsored by InventisBio Co..

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT04097405 is a Phase 1 study that has completed, run by InventisBio Co.. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04097405, a Phase 1 study, has completed, sponsored by InventisBio Co..

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This phase 1 study is a randomized, double-blind, placebo controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy volunteers.

Interventions

  • DRUG Placebo oral tablet
  • DRUG D-0120

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-09-18
Est. Completion 2020-11-18
Phase Phase 1

Sponsor

InventisBio Co.

11 total trials

What the Registry Record Tells You About NCT04097405

The ClinicalTrials.gov registry entry for NCT04097405 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InventisBio Co., which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.

NCT04097405 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04097405 about?

NCT04097405 is a clinical study titled "Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers". This phase 1 study is a randomized, double-blind, placebo controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy volunteers.

What is the current status of trial NCT04097405?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-09-18. Estimated completion is 2020-11-18.

What interventions are being tested in trial NCT04097405?

The interventions under investigation include: Placebo oral tablet (DRUG), D-0120 (DRUG).

Who is sponsoring clinical trial NCT04097405?

This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.